Versant Venture Capital VI Amends Stake in Tempest Therapeutics

TL;DR

Versant Venture Capital VI updated their 13D filing for Tempest Therapeutics. Watch for more details.

AI Summary

Versant Venture Capital VI, L.P. and its affiliates have filed an SC 13D/A amendment on May 13, 2024, related to their holdings in Tempest Therapeutics, Inc. The filing indicates a change in their beneficial ownership, though specific new ownership percentages or dollar amounts are not detailed in this excerpt. This filing follows previous submissions concerning their investment in the company, which was formerly known as Millendo Therapeutics, Inc. and OvaScience, Inc.

Why It Matters

This filing signals a potential shift in control or strategy for Tempest Therapeutics, as a significant investor has updated their disclosures. Investors will be watching for further details on the nature of this change.

Risk Assessment

Risk Level: medium — Changes in beneficial ownership filings can indicate shifts in investor strategy or potential activism, which may impact the company's stock price.

Key Players & Entities

• Versant Venture Capital VI, L.P. (company) — Filer of the SC 13D/A
• Tempest Therapeutics, Inc. (company) — Subject company
• Millendo Therapeutics, Inc. (company) — Former name of subject company
• OvaScience, Inc. (company) — Former name of subject company

FAQ

Key Financial Figures

• $0.001 — me of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securiti

Filing Documents

• d835115dsc13da.htm (SC 13D/A) — 160KB
• 0001193125-24-137304.txt ( ) — 162KB

From the Filing

SC 13D/A 1 d835115dsc13da.htm SC 13D/A SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 3)* Tempest Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 87978U108 (CUSIP Number) Versant Venture Capital VI, L.P. Max Eisenberg One Sansome Street, Suite 1650 San Francisco, CA 94104 415-801-8100 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) March 19, 2024 (Date of Event Which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. * The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act. CUSIP No. 87978U108 13D 1. Name of Reporting Persons Versant Venture Capital VI, L.P. 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) (b) (1) 3. SEC Use Only 4. Source of Funds (See Instructions) WC 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e) 6. Citizenship or Place of Organization Delaware Number of Shares Beneficially Owned by Each Reporting Person With 7. Sole Voting Power 997,940 shares of Common Stock (2) 8. Shared Voting Power 0 9. Sole Dispositive Power 997,940 shares of Common Stock (2) 10. Shared Dispositive Power 0 11. Aggregate Amount Beneficially Owned by Each Reporting Person 997,940 shares of Common Stock (2) 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) 13. Percent of Class Represented by Amount in Row 11 4.5% (3) 14. Type of Reporting Person (See Instructions) PN (1) This Schedule 13D is filed by Versant Venture Capital IV, L.P. (Versant IV), Versant Side Fund IV, L.P. (Side Fund IV), Versant Ventures IV, LLC (LLC IV), Versant Venture Capital VI, L.P. (Versant VI), Versant Ventures VI GP, L.P. (GP VI), Versant Ventures VI GP-GP, LLC (LLC VI), Versant Vantage II, L.P. (Vantage II LP), Versant Vantage II GP, L.P. (Vantage II GP), Versant Vantage II GP-GP, LLC (Vantage II LLC and, with Versant IV, Side Fund IV, LLC IV, Versant VI, GP VI, LLC VI, Vantage II LP and Vantage II GP, collectively, the Reporting Persons). LLC IV is the general partner of Versant IV and Side Fund IV, and LLC IV has voting, investment and dispositive power over the shares held by each of Versant IV and Side Fund IV. LLC VI is the general partner of GP VI, which is the general partner of Versant VI. Each of LLC VI and GP VI share voting, investment and dispositive power over the shares held by Versant VI. Vantage II LLC is the general partner of Vantage II GP, which is the general partner of Vantage II LP. Each of Vantage II LLC and Vantage II GP share voting, investment and dispositive power over the shares held by Vantage II LP. The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13D. (2) These shares are held by Versant VI. LLC VI is the general partner of GP VI, which is the general partner of Versant VI. Each of LLC VI and GP VI share voting, investment and dispositive power over the shares held by Versant VI and as a result may be deemed to have beneficial ownership over such securities. (3) Based on 22,192,026 shares of the Issuers Common Stock outstanding as of March 13, 2024, as set forth in the Issuers annual report on Form 10-K for the year ended December 31, 2023, filed with the United States Securities and Exchange Commission (the Commission) on March 19, 2024 (the Form 10-K). CUSIP No. 87978U108 13D 1. Name of Reporting Persons Versant Ventures VI GP, L.P. 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) (b) (1) 3. SEC Use Only 4. Source of Funds (See Instructions) AF 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e) 6. Citizenship or Place of Organization Delaware Number of Shares Beneficially Owned by Each Reporting Person With 7. Sole Voting Power 0 8. Shared Voting Power 997,940 shares of Common Stock (2) 9. Sole Dispositive Po

View Full Filing

View this SC 13D/A filing on SEC EDGAR